Factors contributing to CSF NfL reduction over time in those starting treatment for multiple sclerosis: An observational study.

Smets, I; Holden, D; Bianchi, L; Ammoscato, F; Allen-Philbey, K; Baker, D; Turner, B; Marta, M; Giovannoni, G; Macdougall, AORCID logo; +3 more...Schmierer, K; Hobart, J; Gnanapavan, S and (2022) Factors contributing to CSF NfL reduction over time in those starting treatment for multiple sclerosis: An observational study. MULTIPLE SCLEROSIS AND RELATED DISORDERS, 57. 103409-. ISSN 2211-0348 DOI: 10.1016/j.msard.2021.103409
Copy

BACKGROUND: In multiple sclerosis (MS) neurofilament light chain (NfL) is a marker of neuronal damage secondary to inflammation and neurodegeneration. NfL levels drop after commencement of disease-modifying treatment, especially the highly active ones. However, the factors that influence this drop are unknown. OBJECTIVE: To examine the patient and treatment-related factors that influence CSF NfL before and after starting treatment. METHODS: Eligible patients across two centres with two CSF NfL measurements, clinical and MRI data were included as part of an observational cohort study. RESULTS: Data were available in 61 patients, of which 40 were untreated at the first CSF sampling (T1) and treated at the second (T2; mean T1-T2: 19 months). CSF NfL reduction correlated with age (beta = 1.24 95%CI(1.07,1.43); R2 = 0.17; p = 0.005), Expanded Disability Status Scale (EDSS) (beta = 1.12 95%CI(1.00,1.25); R2 = 0.21; p = 0.05) and the type of MS (beta = 0.63 95%CI(0.43, 0.92); R2 = 0.12; p = 0.018; reference=relapsing MS). The treatment effect on a baseline NfL of 702 pg/mL was 451 pg/ml 95%CI(374,509) in a 30-year-old versus 228 pg/ml 95%CI(63,350) in a 60-year-old. There was no association in CSF NfL reduction with BMI, disease duration or sex. In cladribine- and alemtuzumab-treated patients, the CSF NfL T2/T1 ratio did not correlate with lymphocyte depletion rate at 23 weeks. CONCLUSIONS: In this observational study, we found that factors reflecting early disease stage, including a younger age, lower disability and relapsing MS were associated with treatment response in CSF NfL. Other factors were not found to be related, including lymphopaenia in highly-active treatments.


picture_as_pdf
Smets_etal_2022_Factors-contributing-to-CSF-NfL.pdf
subject
Accepted Version
error
This is an author accepted manuscript version of an article accepted for publication and following peer review. Please be aware that minor differences may exist between this version and the final version if you wish to cite from it.
Available under Creative Commons: Attribution-NonCommercial-No Derivative Works 3.0

View Download

Atom BibTeX OpenURL ContextObject in Span Multiline CSV OpenURL ContextObject Dublin Core Dublin Core MPEG-21 DIDL Data Cite XML EndNote HTML Citation JSON MARC (ASCII) MARC (ISO 2709) METS MODS RDF+N3 RDF+N-Triples RDF+XML RIOXX2 XML Reference Manager Refer Simple Metadata ASCII Citation EP3 XML
Export

Downloads